<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> associated with <z:hpo ids='HP_0004810'>congenital hypoplastic anemia</z:hpo> (CHA, <z:e sem="disease" ids="C1260899" disease_type="Disease or Syndrome" abbrv="BDS">Blackfan-Diamond syndrome</z:e>) and with the <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e> may require <z:hpo ids='HP_0011010'>chronic</z:hpo> transfusion therapy to sustain life </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0005639'>Hemosiderosis</z:mp> and <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> may result from such a program </plain></SENT>
<SENT sid="2" pm="."><plain>The effect of subcutaneous (SC) <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> (DF) and supplemental oral <z:chebi fb="122" ids="21241">vitamin C</z:chebi> (vit </plain></SENT>
<SENT sid="3" pm="."><plain>C) on urinary iron excretion was studied in two patients with <z:hpo ids='HP_0004810'>congenital hypoplastic anemia</z:hpo> and one patient with <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In the two patients with CHA, urinary iron excretion in response to DF given SC over 24 hours was comparable to the results following intravenous (I.V.) administration </plain></SENT>
<SENT sid="5" pm="."><plain>Both of these cases had low levels of plasma <z:chebi fb="0" ids="22651">ascorbate</z:chebi> on initial evaluation and excreted more iron in response to two different doses of DF after they had received supplemental vit C and their stores were repleted </plain></SENT>
<SENT sid="6" pm="."><plain>Significant iron excretion occurred in <z:hpo ids='HP_0000001'>all</z:hpo> three patients for 12 hours during the SC infusion of DF and for 12 hours after the end of the infusion </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> three patients, increasing the dose of DF up to 3-4 g given SC over 12 hours resulted in a linear increase in iron excretion </plain></SENT>
<SENT sid="8" pm="."><plain>Once <z:mpath ids='MPATH_458'>normal</z:mpath> body stores of <z:chebi fb="0" ids="22651">ascorbate</z:chebi> were achieved by oral supplementation, increasing doses of vit C did not appear to cause a further increment in iron excretion </plain></SENT>
<SENT sid="9" pm="."><plain>DF administered by a slow SC infusion appears to be an effective approach to <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> and <z:mp ids='MP_0005639'>hemosiderosis</z:mp> secondary to <z:hpo ids='HP_0011010'>chronic</z:hpo> transfusions </plain></SENT>
<SENT sid="10" pm="."><plain>Only small amounts of supplemental vit </plain></SENT>
<SENT sid="11" pm="."><plain>C necessary to sustain adequate body stores are required for optimal iron excretion </plain></SENT>
</text></document>